Abstract
Introduction
Glycated hemoglobin can interfere with oxygen delivery and CO2 removal during exercise. Additionally, pancreatic insufficiency increases oxidative stress and exacerbates exercise intolerance in people with cystic fibrosis (PwCF). This investigation sought to test the hypotheses that elevated Hemoglobin A1c (HbA1c) can negatively affect exercise parameters in PwCF and that reductions in oxidative stress can improve tissue oxygenation in individuals with elevated HbA1c.
Methods
Twenty four PwCF were divided into two groups; normal HbA1c <5.7% (N-HbA1c) and elevated HbA1c >5.7% (E-HbA1c). A maximal exercise test was conducted to obtain peak oxygen uptake (VO2peak), VO2 at ventilatory threshold (VT), ventilatory parameters (VE/VCO2 slope and end-tidal CO2 (petCO2)). Near-Infrared Spectroscopy (NIRS) was used to assess muscle oxygenated/deoxygenated hemoglobin during exercise. A subset of individuals with E-HbA1cwere given an antioxidant cocktail (AOC) for 4 weeks to determine the effects on tissue oxygenation during exercise.
Results
A negative relationship between HbA1c and VO2peak at VT was observed (r = −0.511; p = 0.018). In addition, a positive relationship between HbA1c and VE/VCO2 slope (r = 0.587;p = 0.005) and a negative relationship between HbA1c and petCO2 at maximal exercise (r = −0.472;p = 0.031) was observed. N-HbA1c had greater VO2peak (p = 0.021), VO2 at VT (p = 0.004), petCO2 (p = 0.002), and lower VE/VCO2 slope (p = 0.004) compared with E-HbA1c. Muscle deoxygenated hemoglobin at VT was higher in N-HbA1c vs. E-HbA1c and 4 weeks of AOC improved skeletal muscle utilization of oxygen.
Conclusion
Findings demonstrate that glycated hemoglobin may lead to tissue oxygenation impairment and ventilation inefficiency during exercise in PwCF. In addition, antioxidant supplementation may lead to improved tissue oxygenation during exercise.
Keywords
Introduction
Cystic fibrosis (CF) has traditionally been characterized by pulmonary dysfunction, pancreatic insufficiency, and other systemic abnormalities. In addition, exercise intolerance is a common manifestation of CF, and a reduced exercise capacity can predict disease-related morbidity and mortality, independent of lung function.1,2 The availability of oxygen (O2) to the skeletal muscle and removal of metabolic carbon dioxide (CO2) by the lungs are both critical to maintain any type of continuous activity (i.e., exercise). In fact, the assessment of the ventilatory equivalent of carbon dioxide (VE/VCO2) during exercise is an indicator of how adeptly the body can clear CO2 from the lungs, with higher values being predictive of mortality in various patient populations.3–5 Interestingly, a single report has documented that VE/VCO2 can increase overtime in CF without observed changes in exercise capacity. 6 Although the mechanisms that contribute to lower exercise capacity in CF have yet to be fully elucidated, impaired oxygen extraction and utilization of oxygen by skeletal muscle may play an important role. 7 In addition, evaluation of the ventilatory threshold (VT) can be a useful measure of aerobic fitness 8 ; however, no studies have evaluated the importance of muscle oxygen extraction in relation to the VT, when aerobic respiration is the primary source of metabolism.
Oxidative stress is a common phenotype of CF and contributes to pancreatic insufficiency and progressive loss of endocrine function via destruction of insulin-producing β-cells. Indeed, 50% of adults with CF exhibit impaired glucose tolerance and eventually develop cystic fibrosis-related diabetes (CFRD), a clinical manifestation that increases disease severity and contributes to morbidity and mortality9,10 in this patient population. It is unclear, however, whether or not CFRD is associated with exercise capacity with scant evidence to both support and refute the hypothesis.11,12 Although treatment with antioxidants can be protective against diabetic nephropathy in people with diabetes 13 and decrease oxidative stress in people with CF, 14 mechanistic insight into the relationships among oxidative stress, impaired glucose tolerance, and exercise capacity in CF are certainly warranted.
Hemoglobin A1c (HbA1c), a measure of glycated hemoglobin, can be used to evaluate glycemic status in people with CF. Hemoglobin A1c values greater than 5.7%, can predict a positive glucose tolerance test that is diagnostic of CFRD. 14 Glycosylation of hemoglobin allosterically inhibits the hemoglobin molecule, shifting the T-state/R-state equilibrium. 13 Accordingly, it is plausible that glycated hemoglobin may interfere with the ability of the hemoglobin molecule to not only bind, but also release oxygen and carbon dioxide, resulting in impaired oxygen delivery to skeletal muscle and reduced emission of carbon dioxide by the lungs. Thus, the present investigation sought to test the hypotheses that elevated HbA1c reduces both the utilization of oxygen and the removal of carbon dioxide during exercise in people with CF and that reductions in systemic oxidative stress using an antioxidant cocktail (AOC) can improve tissue oxygenation in people with CF that exhibit elevated HbA1c.
Methods
Study participants
Twenty four people with CF (10 males and 14 females) completed the investigation at the Georgia Prevention Institute’s (GPI) Laboratory of Integrative Vascular and Exercise Physiology (LIVEP) at Augusta University. Individuals arrived to the LIVEP in a fasted state after abstaining from exercise for at least 24 h prior to testing. Individuals were instructed to adhere to their normal medications, daily pulmonary treatments, and airway clearance techniques. All protocols were approved by the Institutional Review Board at Augusta University and informed consent/assent was obtained from all individuals and parents of minors. Inclusion criteria required patients to have a clinical diagnosis of CF and be clinically stable for 2 weeks prior to testing. Individuals were excluded if they had a recent CF exacerbation or need for antibiotic treatment within 2 weeks of testing. Following enrollment, individuals were divided into groups based on HbA1c consistent with predictive diagnostic criteria for CFRD 13 ; those with an HbA1c of <5.7% were included in the normal HbA1c group (N-HbA1c), while individuals with HbA1c > 5.7% comprised the elevated HbA1c group (E-HbA1c).
Anthropometric assessment
Upon arrival to the LIVEP, height and weight were determined using a stadiometer and platform scale, and body mass index (BMI) was calculated. Body fat percentage, fat mass, and lean mass were determined using dual energy X-ray absorptiometry (DXA) (QDR-4500W; Hologic, Waltham, MA). Systolic and diastolic blood pressures were obtained using a sphygmomanometer. A venous blood sample was collected from the antecubital fossa to assess blood glucose and HbA1c using standard core laboratory techniques (Laboratory Corporation of American Holdings, Burlington NC). In addition, a fasting lipid profile was obtained and included concentrations of total cholesterol (TC), high-density lipoproteins (HDL), low-density lipoproteins (LDL), triglycerides (TG). Hemoglobin and hematocrit were measured using a HemoPoint H2 analyzer (Stanbio Laboratories).
Pulmonary function test
Following the guidelines set forth by the American Thoracic Society, 15 a pulmonary function assessment was performed to determine forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1 percent predicted, FEV1/FVC, and forced expiratory flow at 25–75% (FEF25-75) in all individuals as previously described. 16
Cardiopulmonary exercise test
All individuals completed an exercise test to volitional fatigue on a cycle ergometer using the Godfrey protocol. During exercise, expired gases were analyzed as 30 s averages using a TruOne® 2400 metabolic cart (Parvo Medics, Sandy UT) to obtain VO2 peak and peak minute ventilation (VE). Additionally, hemodynamics responses were monitored non-invasively both at rest and throughout maximal exercise by patented technology of signal morphology-based impedance cardiography (PhysioFlow®, Ebersviller, France) as previously described by our group. 7 Ventilatory threshold (VT) was calculated using the v-slope method and was used for determination of VO2 at VT. Ventilatory parameters were obtained as a ratio of minute ventilation (VE) to VO2 and VCO2, and the VE/VCO2 slope was calculated. End-tidal CO2 (petCO2) was calculated from expired CO2. Muscle oxygen consumption (mVO2) and concentrations of oxygenated and deoxygenated hemoglobin of the vastus lateralis were determined during exercise in a subset of 13 individuals by assessing the deoxygenated hemoglobin concentration using Near-Infrared Spectroscopy (NIRS) (Portalite, Artinis Medical Systems, Elst, The Netherlands). Near-Infrared Spectroscopy provides a novel, noninvasive assessment of skeletal muscle oxygenation during exercise as previously described in CF by our group. 7
Antioxidant supplementation
A subset of individuals with elevated HbA1c (n = 7) volunteered to ingest an oral AOC (vitamin C 1000 mg, vitamin E 600 IU, and alpha lipoic acid 600 mg) for 4 weeks to determine the role of oxidative stress on tissue oxygenation during exercise; these data were obtained as part of a clinical trial studying the impacts of antioxidant therapy on people with CF (#NCT02690064). We have previously reported the efficacy of this AOC to improve markers of oxidative stress in people with CF. 17
Statistical analysis
All analyses were performed using SPSS Statistics Version 27. To determine differences in participant characteristics and exercise outcomes between the normal HbA1c and elevated HbA1c groups, an analysis of covariance (ANCOVA) was utilized controlling for age, sex, BMI, and percent predicted FEV1. To determine if changes in deoxygenated Hgb during exercise were different between N-HbA1c, E-HbA1c, and individuals taking antioxidants, a two-way (group by time) repeated measures analysis of variance (ANOVA) with a Bonferroni correction was performed. Pearson correlations were performed to assess the relationships between HbA1c (on a continuum with values ranging from 5.1–6.7) and exercise capacity, ventilatory parameters, and hemoglobin desaturation. Effect sizes for differences in VO2 peak, VO2 at VT, VE/VCO2, and petCO2 are reported as Cohen’s d values to represent small (Cohen’s d = 0.2), medium (Cohen’s d = 0.5), and large (Cohen’s d = 0.8) effect sizes. 18 All group data are reported as mean ± standard deviation (SD) unless otherwise noted. All correlative data are reported as the coefficient of determination (r) and significance was set at p < 0.05.
Results
Patient comorbidities, demographics, laboratory values, and pulmonary function testing
Patient demographics and pulmonary function values.
Notes: Values are mean ± SD. BMI, body mass index, SBP, systolic blood pressure, DBP, diastolic blood pressure, GLU, fasting blood glucose, Hgb, hemoglobin, FEV1, forced expiratory volume in 1 s, FVC, forced vital capacity, FEF25-75%, forced expiratory flow over the middle one-half of the FVC. *Significant difference between groups (p < 0.05).
Cardiopulmonary measures at baseline and maximal exercise between groups.
Notes: Values are mean ± SD. HR, heart rate, SV, stroke volume, CO, cardiac output, MAP, mean arterial pressure.
Exercise capacity, ventilatory parameters, and hemoglobin desaturation at VT
Figure 1 illustrates the differences in VO2 peak, ventilatory parameters, and deoxygenated hemoglobin between groups, controlling for lung function, age, and BMI. Exercise capacity (Figure 1(a); p = 0.021, Cohen’s d = 0.796) and exercise capacity at VT (Figure 1(b); p = 0.004, Cohen’s d = 0.783) were both significantly higher in the N-HbA1c group compared with the E-HbA1c group. In addition, VE/VCO2 slope was significantly (Figure 1(c); p = 0.004, Cohen’s d = −0.559) lower and petCO2 (Figure 1(d); p = 0.002, Cohen’s d = 0.754) was higher in the N-HbA1c group compared with the E-HbA1c group. In contrast, no significant difference between ventilation was observed between groups. Figure 2 illustrates the associations between exercise indices and HbA1c corrected for age and BMI. Negative relationships between HbA1c and both VO2 peak (r = −0.411; p = 0.064; Figure 2(a)) and VO2 peak at VT (r = −0.511; p = 0.018; Figure 2(b)) were observed. VE/VCO2 slope was positively correlated (r = 0.587; p = 0.005) with HbA1c (Figure 2(c)) and petCO2 was inversely proportional (r = −0.473; p = 0.031) to HbA1c (Figure 2(d)). Differences in indices of exercise capacity (a–b) and ventilatory parameters (c–d) between individuals in the N-HbA1c and E-HbA1c groups. Associations between exercise variables and HbA1c (%).

Hemoglobin desaturation during maximal exercise
The change in deoxygenated hemoglobin throughout maximal exercise in patients with normal and elevated HbA1c is presented in Figure 3. A significant interaction (p = 0.046) was observed for the deoxygenated hemoglobin response between groups. Specifically, deoxygenated hemoglobin during exercise was greater at 60% (p = 0.007), 80% (p = 0.026), and 100% (p = 0.089) of VO2 max in the N-HbA1c group compared to the E-HbA1c. In addition, Figure 3 illustrates that treatment with 4 weeks of antioxidants in a subgroup of patients (n = 7) with E-HbA1c is able to restore the deoxygenated hemoglobin response to exercise to similar values observed in the N-HbA1c group. In addition, a significant negative association (r = −0.625; p = 0.004) between concentrations of deoxygenated hemoglobin of the vastus lateralis at VT and HbA1c was observed. Deoxygenated hemoglobin concentration by percent VO2 in the N-HbA1c (n = 11) and E-HbA1c (n = 13) groups, and a subset of individuals (n = 7) with an average elevated HbA1c (average HbA1c = 5.8%) following 4-weeks of antioxidant supplementation. *Significant from N-HbA1c and AOC.
Discussion
Exercise intolerance can predict morbidity and mortality in people with CF, independent of lung function.19,20 Although the mechanisms for exercise intolerance in CF have yet to be fully elucidated, adequate tissue oxygenation and efficient removal of metabolically produced carbon dioxide from the body are critical to maintain exercise capacity. Previous research shows that poor glucose control is associated with reduced exercise capacity in children with CF 11 ; however, findings from the present investigation have identified that glycemic status can affect exercise physiology in people with CF. Specifically, individuals in the N-HbA1c group had higher exercise capacity, greater hemoglobin desaturation, decreased CO2 retention, and decreased VE/VCO2 slope compared to individuals in the E-HbA1c group. In addition, present findings demonstrate that supplementation with an AOC for 4 weeks can improve skeletal muscle oxygen utilization during exercise in a subset of individuals with elevated HbA1c.
Hemoglobin A1c and exercise capacity
Findings from the present study demonstrate that higher HbA1c can negatively impact exercise capacity in people with CF. For decades, the conventional wisdom was that poor lung function limits exercise ability in people with CF; however, recent data support that lung dysfunction is not the primary driver for exercise intolerance among people with mild to moderate CF.1,21 Decreased exercise capacity and skeletal muscle dysfunction have been observed in people with Type 2 diabetes and is likely due, in part, to fat infiltration and metabolic dysregulation of the functional muscle. 22 In addition, poor glycemic control, a strong predictor of increased morbidity and mortality, can contribute to worsening of exercise capacity among individuals with Type 2 diabetes. 23 Limited data support the association between CFRD and exercise intolerance in children with CF. 11 However, more recently, no association between CFRD and maximal aerobic capacity was observed in physically active people with CF. 12 Individuals with poor glycemic control in the present study not only had lower exercise capacity compared to those in the N-HbA1c group, but exercise capacity at VT was also lower in the E-HbA1c group. Impairment in exercise capacity at VT is particularly revealing, as this variable is a direct measure of submaximal aerobic exercise tolerance. The body primarily relies on oxygen to produce cellular energy during aerobic exercise; therefore, VO2 at VT is indicative of the body’s availability of oxygen while performing aerobic respiration. 8 These findings suggest that elevated glycosylated hemoglobin can impair oxidative metabolism during exercise in individuals with CF. It is important to note that individuals in the E-HbA1c group had lower FEV1 compared to those in the N-HbA1c group; however, percent predicted FEV1 was similar. Accordingly, the difference in absolute lung function is likely due to the sex differences between groups, as more females were in the E-HbA1c group. Additionally, sex, age, and BMI can contribute to the differences in exercise capacity24–26 reported in people with CF. Accordingly, percent predicted FEV1, sex, age, and BMI were used as covariates in analyses. Indeed, it is important to note that controlling for these variables did not change the overall findings that glycosylated hemoglobin can affect exercise parameters in CF. In general, there are also sex differences between exercise capacity, with men having an overall higher exercise performance than women.27,28 The low number of patients with CF in our area prevented our group from obtaining an equal representation of sex within groups. Furthermore, there was no data on physical activity status in this cohort; however, we understand that physical activity may influence VO2 max in individuals with CF.
Hemoglobin A1c and ventilation efficiency
The mechanism by which oxygen and carbon dioxide are carried in the blood is complex. Briefly, the hemoglobin molecule moves between the T-state/deoxygenated state and the R-state/oxygenated state 29 dependent upon the body’s demand to maintain physiologic homeostasis. As described by the Bohr effect, the presence of excess CO2 in the blood generally decreases the molecule’s affinity for oxygen and promotes release of oxygen to the tissue, while the lack of CO2 increases the molecule’s affinity for oxygen. Similarly, the Haldane effect describes that oxygen-rich hemoglobin has a decreased affinity for carbon dioxide while oxygen-depleted hemoglobin has an increased affinity for carbon dioxide. 30 Therefore, the allostery of the hemoglobin molecule is responsible for oxygen delivery to the tissue as well as transporting carbon dioxide to the lungs for removal. Paradoxically, individuals within the E-HbA1c group had increased carbon dioxide retention but decreased hemoglobin desaturation and subsequent impairment of tissue oxygenation during exercise. It is therefore probable that glycated hemoglobin disrupts the T-state/R-state equilibrium in people with CF. In individuals without CF, studies demonstrate that people with increased HbA1c have decreased tissue oxygen utilization which contributes to increased oxygenated venous blood. 31 Additionally, glucose can alter the quaternary structure of the T-state, leading to higher affinity for oxygen and less tissue oxygenation during physiologic stress. The present investigation demonstrates that HbA1c is associated with not only decreased hemoglobin desaturation, but also abnormal ventilatory parameters during exercise in people with CF. Specifically, these findings demonstrate that individuals within the E-HbA1c group have lower concentrations of muscle deoxygenated hemoglobin during exercise, higher VE/VCO2 slope, and lower petCO2 during exercise compared with those in the N-HbA1c group, independent of changes in ventilation. These data support our hypothesis in people with CF, that impaired glycemic control can contribute to decreases in the (1) unloading oxygen to the skeletal muscle, and (2) expiring carbon dioxide by the lungs during exercise, with both leading to this paradox of the Bohr and Haldane effect.
Hemoglobin A1c and deoxygenated hemoglobin saturation: Role of oxidative stress
Oxidative stress is a common phenotype in both CF and diabetes and can contribute to heightened inflammation and microvascular dysfunction.32,33 Findings from the present investigation have identified that individuals in the E-HbA1c group not only have a lower muscle deoxygenated hemoglobin at VT compared with individuals in the N-HbA1c group, but that the change in deoxygenated hemoglobin throughout exercise was lower in the E-HbA1c group. This finding indicates that skeletal muscle dysfunction may exist even during aerobic exercise when oxygen is the major source of cellular respiration. Interestingly, 4 weeks of treatment with an AOC in individuals with E-HbA1c was able to restore the concentration of deoxygenated hemoglobin during exercise to the levels observed in the N-HbA1c group (Figure 3). Our group has previously published the efficacy of the AOC used in the present study to reduce the characteristic “triplet of doublets” EPR signal, which is proportional to the concentration of O2 centered alkoxyl free radical species. 34 In addition, treatment with the AOC contributes to improvement in vascular endothelial function mediated in people with CF that is mediated by an increase in nitric oxide bioavailability. 17 While no significant relationships were found between concentrations of deoxygenated hemoglobin and HbA1c and the impact of treatment with AOC on deoxygenated hemoglobin, the small sample size of this sub-group analysis likely contributed to this analysis being underpowered. Nonetheless, findings from the present study demonstrate that glycosylated hemoglobin in individuals with CF negatively affects tissue oxygenation during exercise. In addition, the present investigation has provided provocative proof-of-concept data to support that antioxidant supplementation and a subsequent reduction in oxidative stress may improve tissue saturation during exercise. It is plausible to expect that increases in skeletal muscle oxygen utilization, likely influenced by decreased oxidative stress, can increase exercise capacity, and likely explains the differences in VO2 peak between groups. Future studies are certainly needed to provide mechanistic insight into how reducing oxidative stress in these individuals can increase exercise capacity.
Experimental considerations
The present investigation is the first to provide mechanistic insight into how glycated hemoglobin can affect exercise capacity and ventilatory efficiencies in people with cystic fibrosis (PwCF). However, given the nature of this preliminary investigation, there are some limitations to consider when interpreting the data. First, the sample size and open label experimental design to test the hypothesis that reductions in oxidative stress can improve tissue oxygenation during exercise in CF should be considered. Importantly, the effect sizes for the between group comparisons are robust; however, we are unable to determine the impact that sex or genotype may have on the differences between groups. In addition, although the present investigation presents experimental data following antioxidant supplementation in only seven PwCF who exhibit E-HbA1c, the results are extremely compelling. Nonetheless, larger, multi-center, randomized, placebo-controlled clinical trials over a longer period of time are needed to fully exploit this hypothesis and determine whether antioxidant supplementation can also reduce glycated hemoglobin and improve exercise capacity. Second, the present investigation supports that increased glycated hemoglobin can impair exercise capacity in PwCF; however, it is still unclear if exercise capacity is actually impacted in PwCF who have CFRD. It is important to note that only four patients in the present investigation had a clinical diagnosis of CFRD and the use of HbA1c as a diagnostic tool for CFRD has been a matter of debate.35–37 Given the accelerated disease severity in CFRD and the fact that exercise capacity can predict survival in CF, independent of lung function, future studies are needed to understand if and how CFRD affects exercise tolerance in CF. Third, NIRS represents a novel, non-invasive methodology to investigate skeletal muscle O2 delivery and extraction. However, this technique is dependent on the placement and penetration depth of the signal and only provides a global surrogate of tissue perfusion and utilization. The placement of the NIRS on the vastus lateralis muscle was carefully chosen and ultrasound was used to assess the adipose tissue thickness to ensure adequate penetration of the NIRS device. However, molecular and more invasive studies to investigate skeletal muscle perfusion and skeletal muscle oxidative metabolism are needed to identify the specific level of skeletal muscle dysregulation.
Conclusion
The present study has demonstrated that elevated glycosylated hemoglobin plays a negative role in exercise capacity and ventilatory equivalents in both children and adults with CF. An increased concentration of glycated hemoglobin may impair muscle oxygenation, ventilation efficiency, and CO2 elimination during exercise in people with CF. Based on the present findings, it is possible that glycosylation inhibits the ability of the hemoglobin molecule to not only release oxygen to the working muscle but also to unload the carbon dioxide at the lungs. Impaired allostery can lead to decreased utilization of oxygen and increased retention of carbon dioxide, both of which contribute to exercise intolerance in people with CF. Our data also support that reducing oxidative stress can improve oxygen unloading at the muscle during exercise. Decreasing oxidative stress through antioxidant supplementation in people with CFRD may improve exercise capacity, thereby, decreasing their risk for disease-related morbidity and mortality.
Footnotes
Acknowledgments
The authors would like to thank all of the participants and their families for their contribution to this study and dedication to continuing CF research. Results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. Results of the present study do not constitute endorsement by ACSM.
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This project was supported by CF Foundation Therapeutics (Harris14A0 and Harris19A0) and NIH (R21DK100783) to RAH.
